︎




New Draft Guidance

U.S. FDA Issues “Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format” Draft Guidance for Comment


January 2023—The U.S. Food and Drug Administration has issued draft guidance for comment purposes. The guidance includes non-binding recommendations and is accepting comments through 3/14/2023. The document titled: Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format has been made available to assist in the development of the DOSAGE AND ADMINISTRATION section of labeling.


Stay tuned for our blog post detailing the guidance in a comprehensive breakdown and weighing in on some implications the revision to the guidance issued March 29, 2010.

Subscribe to our Newsletter to stay up to date on industry news, human factors webinars, upcoming events, and more.

Next Steps


Do you need assistance navigating FDA guidance on human factors for medical devices? UserWise is available to help and has expertise on multiple international human factors standards. 






︎ UserWise, a ClariMed Company | January 24, 2023

About Us


Our consultants partner with medical device companies to fulfill any and all steps of the Usability Engineering Process.

UserWise offers a wide range of services spanning the product development cycle. Our consultants assist in performing user research, constructing the use-related risk analysis, conducting formative evaluations, executing summative usability validation testing, refining user manuals, compiling the Usability Engineering File and FDA Human Factors/Usability Engineering Submission Report, and so much more. 

Learn more

UserWise, LLC
Office Hours
Monday-Friday 9:00 AM - 5:00 PM PT


Copyright © 2023 UserWise, LLC. All rights reserved.